EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

Core Viewpoint - EyePoint Inc has filed a lawsuit against Ocular Therapeutix, alleging the spread of false or misleading information regarding EyePoint's lead experimental eye drug, Duravyu [1][2]. Group 1: Legal Actions - The lawsuit was filed in Middlesex County Superior Court, Massachusetts, accusing Ocular Therapeutix of defamation, commercial disparagement, and violations of consumer protection law [2][3]. - EyePoint is seeking a court order to stop Ocular Therapeutix from making the alleged false statements, demand a public retraction, and claim monetary damages and legal fees [3]. Group 2: Product Development - EyePoint's Duravyu is currently undergoing late-stage studies for wet age-related macular degeneration (wet AMD) and diabetic macular edema, with data for wet AMD expected to be available by mid-2026 [4]. - Ocular Therapeutix's leading drug, Axpaxli, recently met the main goal of a key late-stage trial, demonstrating its effectiveness in helping patients with wet AMD maintain vision compared to Regeneron's Eylea [4].